The news: Structure Therapeutics’ experimental obesity pill led to an average 12.1% weight loss after 36 weeks on a 120 mg daily dose, according to new mid-stage clinical trial data. Participants on a 240 mg daily dose saw 14.2% average weight loss at 36 weeks.

• The trial included 230 adult participants living with obesity with at least one weight-related comorbidity.
• About 10% of participants discontinued treatment due to side effects like nausea and vomiting.
• Structure’s stock price jumped more than 100% on the trial results.

Why it matters: Today’s most effective weight loss drugs are Novo Nordisk’s and Eli Lilly’s GLP-1 injections, but many people prefer a pill over a shot. A slew of companies are now racing to develop pill versions—daily oral weight loss drugs will capture about 25% share of the obesity medication market by 2030, per Goldman Sachs.

Structure’s trial results stack up well against competitors.

• Lilly's pill, orforglipron, helped patients lose between 9% and 12% of their weight, disappointing investors who wanted to see closer to 15% weight loss.
• Novo’s higher-dose 25-mg “Wegovy pill,” which is currently under FDA review, helped patients lose an average of 16.6% weight loss.
• Discontinuation rates due to side effects are similar across the experimental oral weight loss products.

Implications for weight loss drug developers: Newcomers to the weight loss drug market face key disadvantages, even with strong efficacy data.

For one, entrants will struggle to convince doctors that their pills will be better options than Novo’s or Lilly’s unless clinical results demonstrate a meaningful difference, considering both pharma giants are already trusted by physicians. Additionally, prices of GLP-1s continue to come down amid pressure from the Trump administration. New companies won’t be able to set high-priced launch rates the way Novo and Lilly once did, capping their revenue upside.

For smaller weight loss drug developers that may not have the risk appetite or resources to compete with larger players, the best way to cash in on a market dominated by two giants may be to pursue a partnership or acquisition. See Pfizer’s purchase of small obesity drugmaker Metsera as an example of this.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.